A chronological overview of my scientific publications with verified DOI links — as of April 2026.
2012
Carboxyhemoglobin in medical ICU patients
Critical Care · Fazekas AS, Wewalka M, Zauner C, Funk GC
DOI: 10.1186/cc11138
Retrospective observational study in 868 critically ill patients in Vienna. Survivors showed marginally higher carboxyhemoglobin levels than non-survivors — the differences are statistically significant, but too small to qualify as a clinically useful prognostic marker.
Evaluation of 36 formulas for calculating plasma osmolality
Intensive Care Medicine · Fazekas AS, Funk GC, Klobassa DS et al.
DOI: 10.1007/s00134-012-2691-0
Comparison of 36 published osmolality formulas in 236 patients. Only 4 formulas achieved a mean deviation below 1 mosmol/kg — Zander’s newly developed formula showed the closest agreement with measured osmolality.
2013
Prevalence and prognosis of COPD in critically ill patients (1998–2008)
European Respiratory Journal · Funk GC, Bauer P, Burghuber OC, Fazekas A et al.
DOI: 10.1183/09031936.00226411
Analysis of 194,453 admissions to 87 Austrian ICUs over 11 years. COPD was present in 8.6% of patients, was an independent risk factor for increased mortality and prolonged mechanical ventilation — while risk-adjusted mortality improved over the observation period.
Rising serum sodium and metabolic alkalosis in critically ill patients
Intensive Care Medicine · Lindner G, Schwarz C, Grüssing H, Fazekas A, Funk GC et al.
DOI: 10.1007/s00134-012-2753-3
Retrospective study: ICU-acquired hypernatremia is consistently accompanied by metabolic alkalosis — a previously underappreciated association with differential diagnostic relevance.
2018
Long-term outcomes after acute hypercapnic COPD exacerbation: first-ever NIV episode
Wiener klinische Wochenschrift · Fazekas AS, Aboulghaith M, Kriz RC, Funk GC et al.
DOI: 10.1007/s00508-018-1364-6
Retrospective analysis of 122 COPD patients after a first-ever NIV episode. 40% required rehospitalisation within one year; 2-year survival was 63%. Persistent hypercapnia, low BMI, and respiratory acidosis on admission were the strongest risk factors.
2019
Comparison of RECIST, iRECIST, and PERCIST for PD-1/PD-L1 blockade in NSCLC
Clinical Nuclear Medicine · Beer L, Hochmair M, Fazekas A et al.
DOI: 10.1097/RLU.0000000000002603
Prospective comparison of three response criteria in 42 NSCLC patients receiving immunotherapy. RECIST and PERCIST showed only moderate agreement; in cases of pseudoprogression, metabolic activity on PET/CT may help to correctly classify treatment response.
Brigatinib as second or later line in ALK-rearranged NSCLC: real-world data
Anti-Cancer Drugs · Hochmair M, Weinlinger C, Fazekas A et al.
DOI: 10.1097/CAD.0000000000000787
Real-world analysis of 35 patients. Overall response rate 84.9%, median progression-free survival 9.9 months; brigatinib was effective also after ceritinib and alectinib failure.
2020
Effects of salinomycin and niclosamide on SCLC and circulating tumor cell lines
Investigational New Drugs · Hochmair M, Rath B, Fazekas A, Hamilton G et al.
DOI: 10.1007/s10637-019-00847-8
SCLC circulating tumor cell lines from patients with relapsed disease lack a typical cancer stem cell phenotype — neither in terms of sensitivity to stem cell-selective agents nor surface marker expression.
Rapid responses with larotrectinib in TRK-fusion-positive metastatic lung cancer
Clinical Lung Cancer · Hochmair MJ, Fazekas A, Valipour A et al.
DOI: 10.1016/j.cllc.2019.11.010
Case report: Rapid clinical and radiologic remission under larotrectinib in a patient with TRK-fusion-positive metastatic lung cancer — illustrating the potential of targeted therapy for rare oncogenic drivers.
2024
Metabolic tumor volume and organ involvement predict outcome in NSCLC immunotherapy
European Journal of Radiology · Kifjak D, Hochmair M, Fazekas A et al.
DOI: 10.1016/j.ejrad.2023.111198
Prospective study in 87 NSCLC patients: metabolic tumor volume and number of involved organs are independent predictors of progression-free and overall survival — even after adjustment for PD-L1 expression and neutrophil count.
Leave a Reply